Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
252 stopped studies mapped to Malignant Gastric Neoplasm and descendants · 88% state a reason
Over the 252 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computed
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00800969 | Prospective Evaluation of the Preoperative Lymph Node Staging in Patients With Cancer of… | Phase 2 | withdrawn | Dec 3, 2008 | University of Zurich | not stated | Not stated |
| NCT00524186 | Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced… | Phase 1 | terminated | Sep 3, 2007 | Roswell Park Cancer Institute | PI left institute | Investigator |
| NCT01980810 | First Line Chemotherapy for Advanced Cancer(GC-A-003) | Phase 2 | terminated | Nov 11, 2013 | Chinese Academy of Medical Sciences | recruit too slowly | Enrollment / accrual |
| NCT02080416 | Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors | Early Phase 1 | terminated | Mar 6, 2014 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Very slow accrual; terminated to allow resources to be utilized more effectively on other studies.… | Enrollment / accrual |
| NCT02137343 | A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as…(RILOMET-2) | Phase 3 | terminated | May 13, 2014 | Amgen | All Amgen sponsored AMG102 clinical studies were terminated following a pre-planned Data Monitoring… | Safety / toxicity |
| NCT02720926 | Study of TKI 258 in Combination With Xeloda and Oxaliplatin in Advanced Colorectal and… | Phase 1 | terminated | Mar 28, 2016 | National Cancer Centre, Singapore | Unafavourable toxicity profile | Safety / toxicity |
| NCT00130936 | Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine… | Phase 1 / Phase 2 | terminated | Aug 17, 2005 | AHS Cancer Control Alberta | not stated | Not stated |
| NCT01697072 | First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition…(RILOMET-1) | Phase 3 | terminated | Oct 2, 2012 | Amgen | All Amgen sponsored AMG102 clinical studies were terminated following a pre-planned Data Monitoring… | Safety / toxicity |
| NCT02283359 | Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus | Phase 1 | terminated | Nov 5, 2014 | H. Lee Moffitt Cancer Center and Research Institute | Principal Investigator left the institution | Investigator |
| NCT01716546 | Trial of Panitumumab Cisplatin, Fluourouracil and Docetaxel in Locally Advanced or… | Phase 1 / Phase 2 | terminated | Oct 30, 2012 | Hellenic Oncology Research Group | Not reached the primary endpoint target according to the statistical design | Other (stated, no rule matched) |
| NCT02334332 | Educational Brochure in Preparing Patients With Gastric Cancer and Their Caregivers for… | N/A | withdrawn | Jan 8, 2015 | City of Hope Medical Center | No accrual | Enrollment / accrual |
| NCT00023634 | S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian Cancer | Phase 1 | terminated | Jan 27, 2003 | SWOG Cancer Research Network | lack of accrual | Enrollment / accrual |
| NCT00539968 | A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel… | Phase 1 / Phase 2 | terminated | Oct 5, 2007 | Merck Sharp & Dohme LLC | not stated | Not stated |
| NCT01989858 | ITACA-S2 (Intergroup Trial in Adjuvant Chemotherapy for Adenocarcinoma of the Stomach)(ITACA-S2) | Phase 3 | terminated | Nov 21, 2013 | Mario Negri Institute for Pharmacological Research | lack of clinical cases | Other (stated, no rule matched) |
| NCT00511576 | Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for… | Phase 1 | terminated | Aug 6, 2007 | Mirati Therapeutics Inc. | Celgene terminated its collaboration agreement with MethylGene for the development of MGCD0103. All… | Other (stated, no rule matched) |
| NCT00683787 | Docetaxel With or Without Vandetanib in Treating Patients With Metastatic Stomach Cancer… | Phase 2 | terminated | May 23, 2008 | Roswell Park Cancer Institute | low accrual | Enrollment / accrual |
| NCT01748851 | XELOX Versus FOLFOX for Advanced Gastric Cancer (AGC) | Phase 3 | terminated | Dec 13, 2012 | Dong-A University Hospital | Poor enrollment of patients | Enrollment / accrual |
| NCT02005484 | A Study of Herceptin (Trastuzumab) in Patients With Metastatic or Advanced Gastric Cancer… | Phase 2 | terminated | Dec 9, 2013 | Hoffmann-La Roche | Study terminated due to slow patient recruitment. | Enrollment / accrual |
| NCT02205463 | KD019 and Trastuzumab in Patients With Esophagus, Gastroesophageal Junction and Stomach… | Phase 1 | withdrawn | Jul 31, 2014 | NYU Langone Health | IND application withdrawn | Other (stated, no rule matched) |
| NCT01233505 | Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors | Phase 1 | terminated | Nov 3, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00165594 | A Study of E7070 in Patients With Gastric Cancer | Phase 1 / Phase 2 | terminated | Sep 14, 2005 | Eisai Co., Ltd. | Study was completed. | Other (stated, no rule matched) |
| NCT01070290 | A Study of ARQ 197 Versus Investigator's Choice of Second-Line Chemotherapy in Patients… | Phase 2 | withdrawn | Feb 18, 2010 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | not stated | Not stated |
| NCT01705340 | Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With… | Phase 1 | terminated | Oct 12, 2012 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01010334 | Comparison of Standard of Care or Treatment on Protocol | N/A | terminated | Nov 10, 2009 | New Mexico Cancer Research Alliance | PI deparature and very low (\<2%) accrual rate.(No results required) | Enrollment / accrual |
| NCT00017537 | Vaccine Therapy in Treating Patients With Metastatic or Recurrent Cancer | Phase 1 | withdrawn | Jan 8, 2004 | University of Alabama at Birmingham | not stated | Not stated |
| NCT00896467 | Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer… | — | terminated | May 11, 2009 | Centre Oscar Lambret | not stated | Not stated |
| NCT00098527 | FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction… | Phase 2 | terminated | Dec 8, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00012246 | Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract | Phase 2 | terminated | Jan 27, 2003 | The University of Texas Medical Branch, Galveston | Administratively Terminated | Other (stated, no rule matched) |
| NCT01528501 | Histone Deacetylases - Gastric Cancer (HDAC-GaCa-2008)(HDAC) | Phase 2 | terminated | Feb 8, 2012 | Technical University of Munich | medical/ethical reasons | Other (stated, no rule matched) |
| NCT00087191 | EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or… | N/A | terminated | Jul 12, 2004 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT01611506 | Combination Chemotherapy, Cetuximab and Radiation for Patients With Localized Gastric… | Phase 1 / Phase 2 | terminated | Jun 5, 2012 | Dr Anna Dorothea Wagner | Outcome of EXPAND study (no benefit from adding cetuximab to the first-line chemotherapy in… | Other (stated, no rule matched) |
| NCT01219543 | A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced… | Phase 1 | terminated | Oct 13, 2010 | AstraZeneca | Compound development discontinued | Other (stated, no rule matched) |
| NCT00387348 | Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal… | Phase 3 | terminated | Oct 13, 2006 | Massachusetts General Hospital | DSMB stopped study because placebo arm had more adverse events | Safety / toxicity |
| NCT00004099 | Surgery With or Without Combination Chemotherapy in Treating Patients With Stomach Cancer | Phase 3 | terminated | Jan 27, 2003 | European Organisation for Research and Treatment of Cancer - EORTC | low accrual | Enrollment / accrual |
| NCT00025532 | Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Gastrointestinal Cancer | Phase 1 | withdrawn | Nov 21, 2003 | University of California, San Francisco | not stated | Not stated |
| NCT00080002 | Efficacy of Pegamotecan (PEG-Camptothecin) in Localized or Metastatic Cancer of the… | Phase 2 | terminated | Mar 23, 2004 | Enzon Pharmaceuticals, Inc. | not stated | Not stated |
| NCT00335959 | S0425 Oxaliplatin, Capecitabine, and RT in Treating Patients W/Stomach Cancer That Can Be… | Phase 2 | terminated | Jun 12, 2006 | SWOG Cancer Research Network | Closed due to slow accrual | Enrollment / accrual |
| NCT01031056 | Collection of Biospecimen & Clinical Information in Patients w/ Gastrointestinal Cancers | — | withdrawn | Dec 14, 2009 | Stanford University | Change in research focus | Other (stated, no rule matched) |
| NCT00429078 | Trial of 2nd Generation Anti-CEA Designer T Cells in Gastric Cancer | Phase 1 | withdrawn | Jan 31, 2007 | Roger Williams Medical Center | low accrual | Enrollment / accrual |
| NCT01212887 | Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating… | Phase 1 | terminated | Oct 1, 2010 | Cancer Research UK | due to safety concerns and lack of efficacy | Safety / toxicity |
| NCT00103103 | Bortezomib, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or… | Phase 2 | terminated | Feb 8, 2005 | California Cancer Consortium | not stated | Not stated |
| NCT00209729 | Phase I/II Study of Oral S-1 Plus Docetaxel in Elderly Patients With Advanced Gastric… | Phase 1 / Phase 2 | suspended | Sep 21, 2005 | Hokkaido Gastrointestinal Cancer Study Group | Registration is less | Other (stated, no rule matched) |
| NCT00568529 | Combination of Capecitabine and Oxaliplatin in Patients With Relapsed or Refractory… | Phase 2 | suspended | Dec 6, 2007 | Fudan University | There are not enough patients enrolled. | Enrollment / accrual |
| NCT00359476 | A Study of Vinflunine in Patients With Gastric Cancer | Phase 2 / Phase 3 | terminated | Aug 2, 2006 | Bristol-Myers Squibb | not stated | Not stated |
| NCT00568971 | Study of Weekly DCF to Treat Advanced Gastric Cancer | Phase 2 | terminated | Dec 6, 2007 | Fudan University | The study has finished. | Other (stated, no rule matched) |
| NCT00622804 | Comparison Study for Bile Reflux and Gastric Stasis in Patients After Distal Gastrectomy | Phase 3 | withdrawn | Feb 25, 2008 | The Catholic University of Korea | It was very difficult to enroll patients in this study. | Enrollment / accrual |
| NCT00595985 | Sorafenib as a Second Line Treatment in Patients With Advanced or Metastatic Gastric… | Phase 2 | terminated | Jan 16, 2008 | Fudan University | low response rate, no evidence of PFS or OS improved. | Other (stated, no rule matched) |
| NCT00209612 | Phase I/II Study of Paclitaxel Plus CPT-11 in Pts. With 2nd Line Chemotherapy of… | Phase 1 / Phase 2 | withdrawn | Sep 21, 2005 | Hokkaido Gastrointestinal Cancer Study Group | due to strong side effect | Other (stated, no rule matched) |
| NCT00503321 | Phase II Study of TS-1 Therapy and TS-1+PSK Therapy Against Advanced Gastric Carcinoma(eNCIT-Japan) | Phase 2 / Phase 3 | terminated | Jul 18, 2007 | Eastern Network of Cancer Immunological Therapy, Japan | Patients' enrollment was not sufficient. | Enrollment / accrual |
| NCT00155883 | Bi-Weekly Docetaxel Plus 24-Hour Infusion of High-Dose 5-Fluorouracil / Leucovorin (HDFL)… | Phase 2 | terminated | Sep 12, 2005 | National Taiwan University Hospital | slow a accrul due to many competitive trials. | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jun 23, 2016source: clinicaltrials